- Home
- MFIC vs RIGL Comparison
MFIC vs RIGL Comparison
Compare MFIC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIC | RIGL |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 803.1M | 884.9M |
| IPO Year | 2004 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MFIC | RIGL |
|---|---|---|
| Price | $9.04 | $47.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $11.25 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 492.1K | 231.9K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $35.77 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $9.09 | $24.84 |
| 52 Week High | $12.50 | $52.24 |
Technical Indicators
Market Signals| Indicator | MFIC | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 29.27 | 60.21 |
| Support Level | N/A | $40.05 |
| Resistance Level | $9.95 | $49.10 |
| Average True Range (ATR) | 0.16 | 1.50 |
| MACD | -0.07 | -0.15 |
| Stochastic Oscillator | 4.28 | 51.44 |
Price Performance
Historical ComparisonAbout MFIC MidCap Financial Investment Corporation
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. The investment objective of the company is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.